These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging. Li D; Zou S; Cheng S; Song S; Wang P; Zhu X Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253 [TBL] [Abstract][Full Text] [Related]
3. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891 [TBL] [Abstract][Full Text] [Related]
4. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647 [TBL] [Abstract][Full Text] [Related]
5. Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549 [TBL] [Abstract][Full Text] [Related]
6. Preclinical PET imaging with the novel human antibody Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343 [TBL] [Abstract][Full Text] [Related]
7. Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423 [TBL] [Abstract][Full Text] [Related]
8. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023 [TBL] [Abstract][Full Text] [Related]
9. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Wei J; Wang YH; Lee CY; Truillet C; Oh DY; Xu Y; Ruggero D; Flavell RR; VanBrocklin HF; Seo Y; Craik CS; Fong L; Wang CI; Evans MJ Mol Imaging Biol; 2020 Dec; 22(6):1553-1561. PubMed ID: 32813112 [TBL] [Abstract][Full Text] [Related]
11. Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780 [TBL] [Abstract][Full Text] [Related]
12. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870 [TBL] [Abstract][Full Text] [Related]
13. A Preclinical Assessment of Moroz A; Lee CY; Wang YH; Hsiao JC; Sevillano N; Truillet C; Craik CS; Fong L; Wang CI; Evans MJ Bioconjug Chem; 2018 Oct; 29(10):3476-3482. PubMed ID: 30227708 [TBL] [Abstract][Full Text] [Related]
14. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742 [TBL] [Abstract][Full Text] [Related]
15. Association Between PD-L1 Expression and Metabolic Activity on Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498 [TBL] [Abstract][Full Text] [Related]
16. Probody Therapeutic Design of Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313 [TBL] [Abstract][Full Text] [Related]
17. Folate Receptor α-Targeted Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274 [TBL] [Abstract][Full Text] [Related]
19. Radiolabelling and preclinical characterization of Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805 [TBL] [Abstract][Full Text] [Related]
20. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]